Profile
Gregory D.
Kunst is currently Chief Executive Officer & Director at Valitor, Inc. since 2025 and Director at Pr3vent, Inc. Former positions include Co-Chief Executive Officer & Director at Aurion Biotech, Inc., Global Marketing Director at Alcon, Inc., and Vice President-Global Marketing at Glaukos Corp.
Education includes an MBA from Vanderbilt University and an undergraduate degree from Brigham Young University.
Gregory Kunst active positions
| Companies | Position | Start |
|---|---|---|
Pr3vent, Inc
Pr3vent, Inc Medical/Nursing ServicesHealth Services Provides healthcare technology services | Director/Board Member | - |
Valitor, Inc.
Valitor, Inc. BiotechnologyHealth Technology Operates as a biotechnology company which develops novel methods of modifying therapeutic proteins | Chief Executive Officer | 2025-10-16 |
Former positions of Gregory Kunst
| Companies | Position | End |
|---|---|---|
| GLAUKOS CORPORATION | Sales & Marketing | - |
Aurion Biotech, Inc.
Aurion Biotech, Inc. BiotechnologyHealth Technology Develops advanced cell therapies to treat eye diseases | Chief Executive Officer | - |
Training of Gregory Kunst
Experiences
Positions held
Active
Inactive
Listed companies
Private companies
Linked companies
| Private companies | 6 |
|---|---|
Glaukos Corp.
Glaukos Corp. Medical SpecialtiesHealth Technology Operates as an ophthalmic medical device company | Health Technology |
Vanderbilt University
Vanderbilt University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Brigham Young University
Brigham Young University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Valitor, Inc.
Valitor, Inc. BiotechnologyHealth Technology Operates as a biotechnology company which develops novel methods of modifying therapeutic proteins | Health Technology |
Pr3vent, Inc
Pr3vent, Inc Medical/Nursing ServicesHealth Services Provides healthcare technology services | Health Services |
Aurion Biotech, Inc.
Aurion Biotech, Inc. BiotechnologyHealth Technology Develops advanced cell therapies to treat eye diseases | Health Technology |
- Stock Market
- Insiders
- Gregory Kunst
















